Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease

Journal of Neuroimmunology

Volumn 236, Issue 1-2, 2011, Pages 39-46

  Depboylu, Candan ^a   Schorlemmer, Kathrin ^a   Klietz, Martin ^a   Oertel, Wolfgang H ^a   Weihe, Eberhard ^a   Höglinger, Günter U ^a   Schäfer, Martin K H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Complement system; Dopamine; Innate immune system; Microglia; Neurodegeneration

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; COMPLEMENT COMPONENT C1Q; DOPAMINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; MACROPHAGE; MALE; MICROGLIA; MOUSE; NIGROSTRIATAL DOPAMINERGIC INJURY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; UPREGULATION;

ANIMALS; COMPLEMENT C1Q; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; MPTP POISONING; PARKINSON DISEASE; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 79960156075     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.05.006     Document Type: Article

References (47)

1. Barcia C., Sánchez Bahillo A., Fernández-Villalba E., Bautista V., Poza Y., Poza M., Fernández-Barreiro A., Hirsch E.C., Herrero M.T. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1year after MPTP exposure. Glia 2004, 46:402-409.
2. Barnett M.H., Parratt J.D., Cho E.S., Prineas J.W. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann. Neurol. 2009, 65:32-46.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
4. Bezard E., Dovero S., Imbert C., Boraud T., Gross C.E. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 2000, 38:363-368.
5. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., Loos M., Pandolfi P.P., Walport M.J. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 1998, 19:56-59.
6. Depboylu C., Schäfer M.K., Schwaeble W.J., Reinhart T.A., Maeda H., Mitsuya H., Damadzic R., Rausch D.M., Eiden L.E., Weihe E. Increase of C1q biosynthesis in brain microglia and macrophages during lentivirus infection in the rhesus macaque is sensitive to antiretroviral treatment with 6-chloro-2′, 3′-dideoxyguanosine. Neurobiol. Dis. 2005, 20:12-26.
7. Depboylu C., Schäfer M.K.-H., Arias-Carrión O., Oertel W.H., Weihe E., Höglinger G.U. Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J. Neuropathol. Exp. Neurol. 2011, 70:125-132.
8. Dietzschold B., Schwaeble W., Schäfer M.K., Hooper D.C., Zehng Y.M., Petry F., Sheng H., Fink T., Loos M., Koprowski H., Weihe E. Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis. J. Neurol. Sci. 1995, 130:11-16.
9. Färber K., Cheung G., Mitchell D., Wallis R., Weihe E., Schwaeble W., Kettenmann H. C1q, the recognition subcomponent of the classical pathway of complement, drives microglial activation. J. Neurosci. Res. 2009, 87:644-652.
10. Farkas I., Takahashi M., Fukuda A., Yamamoto N., Akatsu H., Baranyi L., Tateyama H., Yamamoto T., Okada N., Okada H. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J. Immunol. 2003, 170:5764-5771.
11. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol. Immunol. 2004, 41:1089-1098.
12. Gasque P., Dean Y.D., McGreal E.P., VanBeek J., Morgan B.P. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000, 49:171-186.
13. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
14. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
15. Höglinger G.U., Breunig J.J., Depboylu C., Rouaux C., Michel P.P., Alvarez-Fischer D., Boutillier A.L., Degregori J., Oertel W.H., Rakic P., Hirsch E.C., Hunot S. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3585-3590.
16. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
17. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106:518-526.
18. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2:141-151.
19. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
20. Klein M.A., Kaeser P.S., Schwarz P., Weyd H., Xenarios I., Zinkernagel R.M., Carroll M.C., Verbeek J.S., Botto M., Walport M.J., Molina H., Kalinke U., Acha-Orbea H., Aguzzi A. Complement facilitates early prion pathogenesis. Nat. Med. 2001, 7:488-492.
21. Kokovay E., Cunningham L.A. Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol. Dis. 2005, 19:471-478.
22. Kovacs G.G., Gasque P., Ströbel T., Lindeck-Pozza E., Strohschneider M., Ironside J.W., Budka H., Guentchev M. Complement activation in human prion disease. Neurobiol. Dis. 2004, 15:21-28.
23. Kurkowska-Jastrzebska I., Wrońska A., Kohutnicka M., Członkowski A., Członkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 1999, 156:50-61.
24. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 1999, 46:598-605.
25. Liang Y., Li S., Guo Q., Zhang Y., Wen C., Zou Q., Su B. Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity. Brain Res. 2007, 1178:132-140.
26. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999, 5:1403-1409.
27. Loeffler D.A., Camp D.M., Conant S.B. Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study. J. Neuroinflammation 2006, 3:29.
28. Lynch N.J., Willis C.L., Nolan C.C., Roscher S., Fowler M.J., Weihe E., Ray D.E., Schwaeble W.J. Microglial activation and increased synthesis of complement component C1q precedes blood-brain barrier dysfunction in rats. Mol. Immunol. 2004, 40:709-716.
29. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
30. McGeer P.L., Schwab C., Parent A., Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 2003, 54:599-604.
31. Mevorach D., Mascarenhas J.O., Gershov D., Elkon K.B. Complement-dependent clearance of apoptotic cells by human macrophages. J. Exp. Med. 1998, 188:2313-2320.
32. Mitsumoto Y., Watanabe A., Mori A., Koga N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 1998, 248:660-663.
33. Novikova L., Garris B.L., Garris D.R., Lau Y.S. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience 2006, 140:67-76.
34. Petry F., Reid K.B., Loos M. Gene expression of the A- and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. J. Immunol. 1991, 147:3988-3993.
35. Priller J., Flügel A., Wehner T., Boentert M., Haas C.A., Prinz M., Fernández-Klett F., Prass K., Bechmann I., de Boer B.A., Frotscher M., Kreutzberg G.W., Persons D.A., Dirnagl U. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 2001, 7:1356-1361.
36. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 2001, 76:1265-1274.
37. Rodriguez M., Alvarez-Erviti L., Blesa F.J., Rodríguez-Oroz M.C., Arina A., Melero I., Ramos L.I., Obeso J.A. Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol. Dis. 2007, 28:316-325.
38. Rozemuller A.J., Eikelenboom P., Theeuwes J.W., Jansen Steur E.N., de Vos R.A. Activated microglial cells and complement factors are unrelated to cortical Lewy bodies. Acta Neuropathol. 2000, 100:701-708.
39. Schäfer M.K., Schwaeble W.J., Post C., Salvati P., Calabresi M., Sim R.B., Petry F., Loos M., Weihe E. Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J. Immunol. 2000, 164:5446-5452.
40. Schwaeble W., Schäfer M.K., Petry F., Fink T., Knebel D., Weihe E., Loos M. Follicular dendritic cells, interdigitating cells, and cells of the monocyte-macrophage lineage are the C1q-producing sources in the spleen. Identification of specific cell types by in situ hybridization and immunohistochemical analysis. J. Immunol. 1995, 155:4971-4978.
41. Sellar G.C., Blake D.J., Reid K.B. Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q. Biochem. J. 1991, 274:481-490.
42. Simard A.R., Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 2004, 18:998-1000.
43. Stevens B., Allen N.J., Vazquez L.E., Howell G.R., Christopherson K.S., Nouri N., Micheva K.D., Mehalow A.K., Huberman A.D., Stafford B., Sher A., Litke A.M., Lambris J.D., Smith S.J., John S.W., Barres B.A. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131:1164-1178.
44. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-1048.
45. Woodruff T.M., Crane J.W., Proctor L.M., Buller K.M., Shek A.B., de Vos K., Pollitt S., Williams H.M., Shiels I.A., Monk P.N., Taylor S.M. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 2006, 20:1407-1417.
46. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10837-10842.
47. Yamada T., McGeer P.L., McGeer E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol. 1992, 84:100-104.